Breast cancer in young women and prognosis: How important are proliferation markers?

Azim, 2012, Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling, Clin Cancer Res, 18, 1341, 10.1158/1078-0432.CCR-11-2599 Fredholm, 2009, Breast cancer in young women: poor survival despite intensive treatment, PLoS One, 4, 10.1371/journal.pone.0007695 Fredholm, 2016, Long-term outcome in young women with breast cancer: a population-based study, Breast Cancer Res Treat, 160, 131, 10.1007/s10549-016-3983-9 Gnerlich, 2009, Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease, J Am Coll Surg, 208, 341, 10.1016/j.jamcollsurg.2008.12.001 Partridge, 2016, Subtype-dependent relationship between young age at diagnosis and breast cancer survival, J Clin Oncol, 34, 3308, 10.1200/JCO.2015.65.8013 Kroman, 2000, Factors influencing the effect of age on prognosis in breast cancer: population based study, BMJ, 320, 474, 10.1136/bmj.320.7233.474 Anders, 2008, Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression, J Clin Oncol, 26, 3324, 10.1200/JCO.2007.14.2471 Bharat, 2009, Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer, J Surg Oncol, 100, 248, 10.1002/jso.21268 Colleoni, 2002, Very young women (<35 years) with operable breast cancer: features of disease at presentation, Ann Oncol, 13, 273, 10.1093/annonc/mdf039 Sabiani, 2016, Breast cancer in young women: pathologic features and molecular phenotype, Breast, 29, 109, 10.1016/j.breast.2016.07.007 Swain, 2015, Quantitative gene expression by recurrence score in ER-positive breast cancer, by age, Adv Ther, 32, 1222, 10.1007/s12325-015-0268-3 Ahn, 2007, Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society, J Clin Oncol, 25, 2360, 10.1200/JCO.2006.10.3754 Cancello, 2010, Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer, Ann Oncol, 21, 1974, 10.1093/annonc/mdq072 Tang, 2015, Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China, BMC Cancer, 15, 201, 10.1186/s12885-015-1207-z Morrison, 2012, Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer, Br J Cancer, 107, 382, 10.1038/bjc.2012.219 Cheang, 2009, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 101, 736, 10.1093/jnci/djp082 Klintman, 2013, The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer, PLoS One, 8, 10.1371/journal.pone.0081902 Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098 Tobin, 2014, Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients, Mol Oncol, 8, 741, 10.1016/j.molonc.2014.02.007 Coates, 2015, Tailoring therapies–improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221 Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Guo, 2015, Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer, Int J Clin Exp Med, 8, 18656 Agarwal, 2009, Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer, Clin Cancer Res, 15, 3654, 10.1158/1078-0432.CCR-08-3293 Rudolph, 2003, Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer, Int J Cancer, 105, 674, 10.1002/ijc.11132 Strand, 2012, Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer, Breast Cancer Res Treat, 131, 33, 10.1007/s10549-011-1386-5 Voduc, 2008, The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype, Hum Pathol, 39, 1431, 10.1016/j.humpath.2008.03.004 McShane, 2005, REporting recommendations for tumour MARKer prognostic studies (REMARK), Eur J Cancer, 41, 1690, 10.1016/j.ejca.2005.03.032 von Elm, 2007, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet, 370, 1453, 10.1016/S0140-6736(07)61602-X Uhlen, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 10.1126/science.1260419 Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 28, 2784, 10.1200/JCO.2009.25.6529 Prat, 2013, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134 Li, 2015, Clinicopathologic characteristics of oestrogen receptor-positive/progesterone receptor-negative/Her2-negative breast cancer according to a novel definition of negative progesterone receptor status: a large population-based study from China, PLoS One, 10 Maisonneuve, 2014, Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes, Breast Cancer Res, 16, R65, 10.1186/bcr3679 Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393 Honma, 2015, Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy, Breast Cancer, 22, 71, 10.1007/s12282-013-0455-5 Gudlaugsson, 2012, Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer, Histopathology, 61, 1134, 10.1111/j.1365-2559.2012.04329.x Knutsvik, 2014, Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays, PLoS One, 9, 10.1371/journal.pone.0112121 Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Ahlin, 2007, Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?, Histopathology, 51, 491, 10.1111/j.1365-2559.2007.02798.x Michalides, 2002, Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment, Br J Cancer, 86, 402, 10.1038/sj.bjc.6600072 Mu, 2015, A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer, Ann Diagn Pathol, 19, 243, 10.1016/j.anndiagpath.2015.05.002 Sun, 2017, Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: a meta-analysis, Med Baltim, 96, e6860, 10.1097/MD.0000000000006860 Li, 2016, Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers, Am J Transl Res, 8, 142 Gao, 2013, Prognostic value of cyclin E expression in breast cancer: a meta-analysis, Tumour Biol, 34, 3423, 10.1007/s13277-013-0915-8 Sapino, 2006, Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure, Virchows Arch, 449, 288, 10.1007/s00428-006-0233-2 Batistatou, 2013, Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays, Anticancer Res, 33, 2139 Kim, 2001, Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer, Eur J Surg Oncol, 27, 464, 10.1053/ejso.2001.1137 Lindahl, 2004, Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer, Carcinogenesis, 25, 375, 10.1093/carcin/bgh019 Nielsen, 1996, Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status, Br J Cancer, 74, 874, 10.1038/bjc.1996.451 Hunt, 2005, Cyclin E as a prognostic and predictive marker in breast cancer, Semin Cancer Biol, 15, 319, 10.1016/j.semcancer.2005.04.007 Lundgren, 2015, Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study, Acta Oncol, 54, 538, 10.3109/0284186X.2014.965274 Keyomarsi, 2002, Cyclin E and survival in patients with breast cancer, N Engl J Med, 347, 1566, 10.1056/NEJMoa021153 Fasching, 2011, Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment, BMC Cancer, 11, 486, 10.1186/1471-2407-11-486 Smith, 2000, Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations, Anticancer Res, 20, 2537 Hwang, 2003, Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients, Pathol Int, 53, 74, 10.1046/j.1440-1827.2003.01441.x